Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 2/2014

01-08-2014

A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban

Author: Reinhold Kreutz

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2014

Login to get access

Abstract

Altering doses and regimens of a drug has consequences for the drug’s pharmacokinetic and pharmacodynamic profile. Based on a half-life of 5–13 h, it is expected that the Factor Xa inhibitor rivaroxaban would be best suited to a twice-daily rather than a once-daily dose regimen. However, although rivaroxaban is used as a twice-daily regimen for the initial treatment of venous thromboembolism (VTE) and secondary prevention after acute coronary syndromes, the approved dosing is once-daily for prevention of VTE after orthopaedic surgery, long-term secondary prevention of VTE and stroke prevention in patients with non-valvular atrial fibrillation. Rivaroxaban dosing was based on the evaluation of the efficacy and safety of several rivaroxaban doses and regimens in phase II trials. A clear overall advantage of twice-daily dosing compared with once-daily dosing was not documented for indications for which once-daily dosing was subsequently selected. Once-daily dosing was therefore selected for these indications because it is expected to be associated with better compliance than twice-daily dosing, and potentially, with improved outcomes. These studies and data obtained with another Factor Xa inhibitor, edoxaban, in addition to previous experience with low molecular weight heparins, indicate that the clinical impact of once-daily versus twice-daily doses on outcome in terms of efficacy and safety cannot be reliably predicted from pharmacology data, e.g. elimination half-life, obtained during pre-clinical and early phase I clinical studies but rather should be ascertained empirically in phase II and III clinical trials.
Literature
1.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:160S–198SPubMedCrossRef
2.
Hylek EM (2009) The need for new oral anticoagulants in clinical practice. J Cardiovasc Med (Hagerstown) 10:605–609CrossRef
3.
Dyke CK, Steinhubl SR, Kleiman NS et al (2006) First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug–antidote pair for the controlled regulation of Factor IXa activity. Circulation 114:2490–2497PubMedCrossRef
4.
Eriksson BI, Dahl OE, Lassen MR et al (2008) Partial Factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost 6:457–463PubMedCrossRef
5.
Goto S (2006) Factor XIa as a possible new target of antithrombotic therapy. J Thromb Haemost 4:1494–1495PubMedCrossRef
6.
Schumacher WA, Seiler SE, Steinbacher TE et al (2007) Antithrombotic and hemostatic effects of a small molecule Factor XIa inhibitor in rats. Eur J Pharmacol 570:167–174PubMedCrossRef
7.
Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F (2011) The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat Rev Drug Discov 10:61–75PubMedCrossRef
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Raghavan N, Frost CE, Yu Z et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81PubMedCrossRef
18.
Pinto DJ, Orwat MJ, Koch S et al (2007) Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation Factor Xa. J Med Chem 50:5339–5356PubMedCrossRef
19.
Frost C, Yu Z, Moore K et al (2007) Apixaban, an oral direct Factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost 5(Suppl 2):abstract P-M-664
20.
Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–399PubMedCrossRef
21.
Stangier J, Stähle H, Rathgen K, Fuhr R (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:47–59PubMedCrossRef
22.
23.
Ogata K, Mendell-Harary J, Tachibana M et al (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743–753PubMedCrossRef
24.
Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880PubMedCrossRef
25.
Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F (2011) Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50:675–686PubMedCrossRef
26.
Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 78:412–421PubMedCrossRef
27.
Kubitza D, Becka M, Roth A, Mueck W (2008) Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 24:2757–2765PubMedCrossRef
28.
29.
30.
31.
Ahrens I, Bode C (2012) Oral anticoagulation with edoxaban. Focus on current phase III clinical development. Hamostaseologie 32:212–215PubMedCrossRef
32.
Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9–19PubMedCrossRef
33.
34.
Wang X, Hochhaus A, Kantarjian HM et al (2008) Dasatinib pharmacokinetics and exposure–response (E–R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). J Clin Oncol 26:175SCrossRef
35.
Shah NP, Kantarjian HM, Kim DW et al (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204–3212PubMedCrossRef
36.
37.
Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:625–651PubMedCrossRef
38.
Weitz JI, Connolly SJ, Patel I et al (2010) Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 104:633–641PubMedCrossRef
39.
Salazar DE, Mendell J, Kastrissios H et al (2012) Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 107:925–936PubMedCrossRef
40.
Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2007) Pharmacology of the oral, direct Factor Xa inhibitor rivaroxaban—effect of extreme age and gender. Hämostaseologie 27:A40 abstract P004
41.
Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47:218–226PubMedCrossRef
42.
Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk H (2007) Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban—an oral, direct Factor Xa inhibitor. J Thromb Haemost 5(Suppl 2):abstract P-M-635
43.
Kubitza D, Becka M, Mueck W et al (2010) Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 70:703–712PubMedCentralPubMedCrossRef
44.
Graff J, von Hentig N, Misselwitz F et al (2007) Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 47:1398–1407PubMedCrossRef
45.
Lang D, Freudenberger C, Weinz C (2009) In vitro metabolism of rivaroxaban—an oral, direct Factor Xa inhibitor—in liver microsomes and hepatocytes of rat, dog and man. Drug Metab Dispos 37:1046–1055PubMedCrossRef
46.
Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D (2009) Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 37:1056–1064PubMedCrossRef
47.
Kreutz R (2012) Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 26:27–32PubMedCrossRef
48.
Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M (2007) Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct Factor Xa inhibitor—in healthy subjects. Int J Clin Pharmacol Ther 45:335–344PubMedCrossRef
49.
Mueck W, Eriksson BI, Bauer KA et al (2008) Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct Factor Xa inhibitor—in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 47:203–216PubMedCrossRef
50.
Mueck W, Borris LC, Dahl OE et al (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100:453–461PubMed
51.
Turpie AGG, Esmon C (2011) Venous and arterial thrombosis—pathogenesis and the rationale for anticoagulation. Thromb Haemost 105:586–596PubMedCrossRef
52.
53.
Hamm CW, Bassand JP, Agewall S et al (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999–3054PubMedCrossRef
54.
Steg PG, James SK, Atar D et al (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 33:2569–2619PubMedCrossRef
55.
Anderson JL, Adams CD, Antman EM et al (2011) 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:e426–e579PubMedCrossRef
56.
Eriksson BI, Borris L, Dahl OE et al (2006) Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4:121–128PubMedCrossRef
57.
Turpie AGG, Fisher WD, Bauer KA et al (2005) BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3:2479–2486PubMedCrossRef
58.
Eriksson BI, Borris LC, Dahl OE et al (2006) A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114:2374–2381PubMedCrossRef
59.
Eriksson BI, Borris LC, Dahl OE et al (2007) Dose-escalation study of rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120:685–693PubMedCrossRef
60.
Agnelli G, Gallus A, Goldhaber SZ et al (2007) Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116:180–187PubMedCrossRef
61.
Büller HR, Lensing AW, Prins MH et al (2008) A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study. Blood 112:2242–2247PubMedCrossRef
62.
Mega JL, Braunwald E, Mohanavelu S et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29–38PubMedCrossRef
63.
Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775PubMedCrossRef
64.
Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39PubMedCrossRef
65.
Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2786PubMedCrossRef
66.
Turpie AGG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680PubMedCrossRef
67.
The EINSTEIN Investigators (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510CrossRef
68.
The EINSTEIN–PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297CrossRef
69.
Camm AJ, Lip GYH, De Caterina R et al (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747PubMedCrossRef
70.
Torbicki A, Perrier A, Konstantinides S et al (2008) Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J 29:2276–2315PubMedCrossRef
71.
Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e419S–e494SPubMedCentralPubMedCrossRef
72.
You JJ, Singer DE, Howard PA et al (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e531S–e575SPubMedCentralPubMedCrossRef
73.
ROCKET AF Study Investigators (2010) Rivaroxaban-once daily, oral, direct Factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159:340–347CrossRef
74.
Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891PubMedCrossRef
75.
Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL (2009) Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 54:95–109PubMedCrossRef
76.
Eriksson BI, Kakkar AK, Turpie AGG et al (2009) Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 91:636–644PubMedCrossRef
77.
Turpie AGG, Lassen MR, Eriksson BI et al (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 105:444–453PubMedCrossRef
78.
Turpie AGG, Schmidt A, Rud M et al (2012) Rivaroxaban for thromboprophylaxis after total hip or knee replacement surgery: comparison of outcomes of the XAMOS and RECORD studies. Blood 120:abstract 500CrossRef
79.
Fox KAA, Piccini JP, Wojdyla D et al (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32:2387–2394PubMedCrossRef
80.
Gibson CM (2011) Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome—thrombolysis in myocardial infarction 51 trial (ATLAS ACS 2-TIMI 51): a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. http://​networking.​americanheart.​org/​files/​541. Accessed 27 June 2012
81.
Merlini PA, Bauer KA, Oltrona L et al (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61–68PubMedCrossRef
82.
Skeppholm M, Kallner A, Malmqvist K, Blombäck M, Wallén H (2011) Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome? Thromb Res 128:483–489PubMedCrossRef
83.
Falck-Ytter Y, Francis CW, Johanson NA et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e278S–e325SPubMedCentralPubMedCrossRef
84.
Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L (2007) Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 23:83–91PubMedCrossRef
85.
Amouyel P, Mismetti P, Langkilde LK, Jasso-Mosqueda G, Nelander K, Lamarque H (2009) INR variability in atrial fibrillation: a risk model for cerebrovascular events. Eur J Intern Med 20:63–69PubMedCrossRef
86.
Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R (2012) Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 28:669–680PubMedCrossRef
87.
Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS (2012) Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 29:675–690PubMedCrossRef
Metadata
Title
A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban
Author
Reinhold Kreutz
Publication date
01-08-2014
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2014
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-013-1029-2

Other articles of this Issue 2/2014

Journal of Thrombosis and Thrombolysis 2/2014 Go to the issue

OriginalPaper

Clinical significance of circulating blood and endothelial cell microparticles in sickle-cell disease

OriginalPaper

Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss

OriginalPaper

Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia

OriginalPaper

Compartment syndrome following thrombolysis: clinical features and associated conditions

OriginalPaper

Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests

OriginalPaper

Hemostasis, cancer, and ABO blood group: the most recent evidence of association
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits